{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T19:10:25Z","timestamp":1650481825593},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T00:00:00Z","timestamp":1414540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s00292-014-1992-1","type":"journal-article","created":{"date-parts":[[2014,10,27]],"date-time":"2014-10-27T17:22:14Z","timestamp":1414430534000},"page":"271-276","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Globoside als entscheidende Mediatoren in der Pathophysiologie des Shiga-Toxin-assoziierten akuten Nierenversagens und des Morbus Fabry"],"prefix":"10.1007","volume":"35","author":[{"given":"S.","family":"Porubsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,29]]},"reference":[{"key":"1992_CR1","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1128\/IAI.18.3.775-779.1977","volume":"18","author":"Konowalchuk","year":"1977","unstructured":"Konowalchuk J, Speirs JI, Stavric S (1977) Vero response to a cytotoxin of Escherichia coli. Infect Immun 18:775\u2013779","journal-title":"Infect Immun"},{"key":"1992_CR2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/infdis\/151.5.775","volume":"151","author":"Karmali","year":"1985","unstructured":"Karmali MA, Petric M, Lim C et al (1985) The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 151:775\u2013782","journal-title":"J Infect Dis"},{"key":"1992_CR3","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/oxfordjournals.aje.a010082","volume":"150","author":"Michino","year":"1999","unstructured":"Michino H, Araki K, Minami S et al (1999) Massive outbreak of Escherichia coli O157:H7 infection in schoolchildren in Sakai City, Japan, associated with consumption of white radish sprouts. Am J Epidemiol 150:787\u2013796","journal-title":"Am J Epidemiol"},{"key":"1992_CR4","doi-asserted-by":"crossref","unstructured":"Obrig TG (2011) Escherichia coli Shiga toxin mechanisms of action in renal disease. Toxins (Basel) 2:2769\u20132794","DOI":"10.3390\/toxins2122769"},{"key":"1992_CR5","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1106483","volume":"365","author":"Frank","year":"2011","unstructured":"Frank C, Werber D, Cramer JP et al (2011) Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 365:1771\u20131780","journal-title":"N Engl J Med"},{"key":"1992_CR6","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1084\/jem.163.6.1391","volume":"163","author":"Jacewicz","year":"1986","unstructured":"Jacewicz M, Clausen H, Nudelman E et al (1986) Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J Exp Med 163:1391\u20131404","journal-title":"J Exp Med"},{"key":"1992_CR7","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/358510a0","volume":"358","author":"Sandvig","year":"1992","unstructured":"Sandvig K, Garred O, Prydz K et al (1992) Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature 358:510\u2013512","journal-title":"Nature"},{"key":"1992_CR8","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","volume":"364","author":"Lapeyraque","year":"2011","unstructured":"Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al (2011) Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364:2561\u20132563","journal-title":"N Engl J Med"},{"key":"1992_CR9","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","volume":"27","author":"Kielstein","year":"2012","unstructured":"Kielstein JT, Beutel G, Fleig S et al (2012) Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 27:3807\u20133815","journal-title":"Nephrol Dial Transplant"},{"key":"1992_CR10","doi-asserted-by":"crossref","first-page":"e4565","DOI":"10.1136\/bmj.e4565","volume":"345","author":"Menne","year":"2012","unstructured":"Menne J, Nitschke M, Stingele R et al (2012) Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 345:e4565","journal-title":"BMJ"},{"key":"1992_CR11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/path.4388","volume":"234","author":"Porubsky","year":"2014","unstructured":"Porubsky S, Federico G, M\u00fcthing J et al (2014) Direct acute tubular damage contributes to Shiga-toxin-mediated kidney failure. J Pathol 234:120\u2013133. doi:10.1002\/path.4388","journal-title":"J Pathol"},{"key":"1992_CR12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0022-2275(20)43219-5","volume":"31","author":"Hozumi","year":"1990","unstructured":"Hozumi I, Nishizawa M, Ariga T et al (1990) Biochemical and clinical analysis of accumulated glycolipids in symptomatic heterozygotes of angiokeratoma corporis diffusum (Fabry\u2019s disease) in comparison with hemizygotes. J Lipid Res 31:335\u2013340","journal-title":"J Lipid Res"},{"key":"1992_CR13","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/S0021-9258(18)51888-3","volume":"238","author":"Sweeley","year":"1963","unstructured":"Sweeley CC, Klionsky B (1963) Fabry\u2019s disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem 238:3148\u20133150","journal-title":"J Biol Chem"},{"key":"1992_CR14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2133.1898.tb16317.x","volume":"10","author":"Anderson","year":"1898","unstructured":"Anderson W (1898) A case of \u201eangeio-keratoma\u201c. Br J Dermatol 10:113\u2013117","journal-title":"Br J Dermatol"},{"key":"1992_CR15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01986897","volume":"43","author":"Fabry","year":"1898","unstructured":"Fabry J (1898) Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae) (A contribution to knowledge on the purpura haemorrhagica nodularis (purpura papulosa haemorrhagica Hebrae)). Arch Dermatol Syph 43:187\u2013200","journal-title":"Arch Dermatol Syph"},{"key":"1992_CR16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","volume":"122","author":"Schiffmann","year":"2009","unstructured":"Schiffmann R (2009) Fabry disease. Pharmacol Ther 122:65\u201377","journal-title":"Pharmacol Ther"},{"key":"1992_CR17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev.med.57.110104.115650","volume":"57","author":"Brady","year":"2006","unstructured":"Brady RO (2006) Enzyme replacement for lysosomal diseases. Annu Rev Med 57:283\u2013296","journal-title":"Annu Rev Med"},{"key":"1992_CR18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","volume":"8","author":"Rombach","year":"2013","unstructured":"Rombach SM, Smid BE, Bouwman MG et al (2013) Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 8:47","journal-title":"Orphanet J Rare Dis"},{"key":"1992_CR19","first-page":"CD006663","volume":"2","author":"El","year":"2013","unstructured":"El Dib RP, Nascimento P, Pastores GM (2013) Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2:CD006663","journal-title":"Cochrane Database Syst Rev"},{"key":"1992_CR20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1750-1172-8-29","volume":"8","author":"Rombach","year":"2013","unstructured":"Rombach SM, Hollak CE, Linthorst GE et al (2013) Cost-effectiveness of enzyme replacement therapy for Fabry disease. Orphanet J Rare Dis 8:29","journal-title":"Orphanet J Rare Dis"},{"key":"1992_CR21","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1098\/rstb.2003.1279","volume":"358","author":"Platt","year":"2003","unstructured":"Platt FM, Jeyakumar M, Andersson U et al (2003) Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philos Trans R Soc Lond B Biol Sci 358:947\u2013954","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"1992_CR22","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/pds.1779","volume":"18","author":"Hollak","year":"2009","unstructured":"Hollak CE, Hughes D, Schaik IN van et al (2009) Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoepidemiol Drug Saf 18:770\u2013777","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1992_CR23","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","volume":"94","author":"Ohshima","year":"1997","unstructured":"Ohshima T, Murray GJ, Swaim WD et al (1997) alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A 94:2540\u20132544","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1992_CR24","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1073\/pnas.0611139104","volume":"104","author":"Porubsky","year":"2007","unstructured":"Porubsky S, Speak AO, Luckow B et al (2007) Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc Natl Acad Sci U S A 104:5977\u20135982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1992_CR25","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.4049\/jimmunol.1201483","volume":"189","author":"Porubsky","year":"2012","unstructured":"Porubsky S, Speak AO, Salio M et al (2012) Globosides but not isoglobosides can impact the development of invariant NKT cells and their interaction with dendritic cells. J Immunol 189:3007\u20133017","journal-title":"J Immunol"},{"key":"1992_CR26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00441-014-1922-9","volume":"358","author":"Porubsky","year":"2014","unstructured":"Porubsky S, Jennemann R, Lehmann L et al (2014) Depletion of globosides and isoglobosides fully reverts the morphologic phenotype of Fabry disease. Cell Tissue Res 358:217\u2013227","journal-title":"Cell Tissue Res"}],"container-title":["Der Pathologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-014-1992-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00292-014-1992-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-014-1992-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T18:51:34Z","timestamp":1650480694000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00292-014-1992-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,29]]},"references-count":26,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["1992"],"URL":"https:\/\/doi.org\/10.1007\/s00292-014-1992-1","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,29]]}}}